Should you hold Aprea Therapeutics (APRE) stock?
The consensus among Wall Street analysts is that investors should "hold" Aprea Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APRE, but not buy additional shares or sell existing shares. View analyst ratings for Aprea Therapeutics or view top-rated stocks.
Where can I buy shares of APRE?
Shares of APRE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What happened to Aprea Therapeutics?
The company’s Phase 3 trial enrolled 154 mutant-MDS patients. In November, Aprea Therapeutics reported a third quarter net loss of $12.3 million, or 58 cents a share, compared with a loss of $6.2 million, or $5.29 a share, in the year-earlier quarter. The company went public in October 2019.
What was the price of the APRE IPO?
(APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO.
Why did apre stock drop?
Shares of clinical-stage biopharmaceutical company, Aprea Therapeutics, Inc APRE, plummeted 78% after it announced that the late-stage study evaluating the safety and efficacy of lead candidate, eprenetapopt, combined with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS) failed to meet ...
Is apre a good stock to buy?
Aprea Therapeutics Inc (NASDAQ:APRE) The 2 analysts offering 12-month price forecasts for Aprea Therapeutics Inc have a median target of 1.50, with a high estimate of 2.00 and a low estimate of 1.00. The median estimate represents a +83.46% increase from the last price of 0.82.
How do I buy stock in apre?
Shares of APRE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Is APRE stock a buy right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently...
Will Aprea Therapeutics' stock price go up in 2022?
5 brokers have issued twelve-month price targets for Aprea Therapeutics' stock. Their forecasts range from $2.00 to $4.00. On average, they expect...
How has Aprea Therapeutics' stock price performed in 2022?
Aprea Therapeutics' stock was trading at $2.87 at the start of the year. Since then, APRE shares have decreased by 70.4% and is now trading at $0.8...
When is Aprea Therapeutics' next earnings date?
Aprea Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for...
How were Aprea Therapeutics' earnings last quarter?
Aprea Therapeutics, Inc. (NASDAQ:APRE) announced its quarterly earnings results on Monday, May, 16th. The company reported ($0.36) EPS for the quar...
Who are Aprea Therapeutics' key executives?
Aprea Therapeutics' management team includes the following people: Dr. Oren Gilad Ph.D. , Co-Founder, Chief Exec. Officer, Pres and Director Dr....
Who are some of Aprea Therapeutics' key competitors?
Some companies that are related to Aprea Therapeutics include Oncternal Therapeutics (ONCT) , Genprex (GNPX) , Infinity Pharmaceuticals (INFI) ,...
What other stocks do shareholders of Aprea Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV) ,...
When did Aprea Therapeutics IPO?
(APRE) raised $52 million in an initial public offering on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2....
Is Aprea Therapeutics stock a Buy, Sell or Hold?
Aprea Therapeutics stock has received a consensus rating of hold. The average rating score is and is based on 1 buy ratings, 8 hold ratings, and 1...
What was the 52-week low for Aprea Therapeutics stock?
The low in the last 52 weeks of Aprea Therapeutics stock was 0.62. According to the current price, Aprea Therapeutics is 128.61% away from the 52-w...
What was the 52-week high for Aprea Therapeutics stock?
The high in the last 52 weeks of Aprea Therapeutics stock was 7.80. According to the current price, Aprea Therapeutics is 10.22% away from the 52-w...
What are analysts forecasts for Aprea Therapeutics stock?
The 10 analysts offering price forecasts for Aprea Therapeutics have a median target of 13.70, with a high estimate of 37.00 and a low estimate of...
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study
FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies
The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.
What is the increase in G&A expenses?
The FDA removed the full clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. The agency issued a clinical hold on the study in August.
Is Aprea Therapeutics a phase 1/2 trial?
The increase in G&A expenses was primarily due to increases in non-cash stock-based compensation and insurance expense.Net loss: Net loss was $9.7 million, or $0.46 per share for the quarter ended March 31, 2021, compared to a net loss of $9.4 million, or $0.45 per share for the quarter ended March 31, 2020.
What is the increase in G&A expenses?
Aprea Therapeutics Inc (NASDAQ: APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate. The trial is assessing eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML. In 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37%. The composite rate of CR plus CR with incomplete hematologic recovery (CRi), CR/CRi
When is Aprea R&D day 2021?
The increase in G&A expenses was primarily due to increases in non-cash stock-based compensation and insurance expense.Net loss: Net loss was $9.7 million, or $0.46 per share for the quarter ended March 31, 2021, compared to a net loss of $9.4 million, or $0.45 per share for the quarter ended March 31, 2020.
59 Biggest Movers From Yesterday
ET on Thursday, April 22, 2021.
40 Stocks Moving In Monday's Mid-Day Session
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.
Signals & Forecast
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction.
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Aprea Therapeutics Inc.
Is Aprea Therapeutics Inc. stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Insiders are neutral selling more shares than they are buying in Aprea Therapeutics Inc
Aprea Therapeutics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 100 trades there were 4.45 million shares bought and 6.33 million shares sold. The last trade was done 83 days ago by Korbel Gregory Alan who sold 27.5 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!